Headline results for the third quarter:
Biopharma sales: €10.7 billion, down 4.1%
Overall revenue: €12 billion, down 4.1%
Profit: €2.5 billion, up 21.6%
Note: All changes are versus the prior-year period unless otherwise stated
CEO Paul Hudson noted that Dupixent, the launch of Beyfortus and “strong uptake” of Altuviio “were key drivers in the quarter,” which more than offset generic competition to Aubagio in the US. The executive added “we enter a compelling next chapter,” with the company announcing Friday that it split off its consumer healthcare division into a separate unit as part of plans to increase R&D investment in its biopharma business. While exact details are still under review, the most likely path is the creation of a listed entity headquartered in France, at the earliest in the fourth quarter of 2024.
Specialty care unit: €4.6 billion, up 5.3%
General medicines unit: €3 billion, down 13.8%
Lantus: €343 million, down 38.6% Toujeo: €265 million, down 12.8% Plavix: €218 million, down 5.2% Vaccines division: €3.1 billion, down 6.5%
Consumer healthcare: €1.2 billion, down 4.2%
Sales in China: €728 million, down 2.5% on a constant exchange rate (CER) basis
Sanofi confirmed that it expects earnings per share for the full year to grow at a mid-single digit percentage on a CER basis, including approximately €400 million in expected one-off COVID-19 vaccine revenues in the fourth quarter. Management also estimates that the negative currency impact on 2023 earnings will be between 6% and 7%, versus prior guidance of 6.5% to 7.5%.